

Design of Indigenous ELISA Using Tachyzoites from the RH Strain of *Toxoplasma gondii* and Comparison with Commercial Kits in Ahvaz, Southwest of Iran, 2015

Niloofer Mohammadpour,¹ Jasem Saki,^{1,2,*} Abdollah Rafiei,² Ali Khodadadi,³ Mehdi Tavalla,¹ and Bahman Cheraghian⁴

¹Department of Medical Parasitology, Faculty of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

²Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

³Department of Immunology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

⁴Department of Epidemiology and Biostatistics, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran

*Corresponding author: Jasem Saki, Health Research Institute, Infectious and Tropical Diseases Research Center, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, IR Iran. Tel: +98-9127166933, E-mail: jasem.saki@gmail.com

Received 2016 January 26; Revised 2016 June 07; Accepted 2016 September 06.

Abstract

Background: *Toxoplasma gondii* is one of the most common causes of latent infections in humans worldwide. Detecting anti-*Toxoplasma* antibodies in serum using serological tests is a common method to diagnose toxoplasmosis.

Objectives: In the present study, an indigenous ELISA kit was prepared using tachyzoites from the RH strain of *T. gondii*, and its sensitivity and specificity were compared with those of commercial kits.

Methods: To produce antigens, 0.02 mL of locally isolated *T. gondii* RH strain parasites along with 10⁹ tachyzoites were injected into the peritoneal cavities of 50 laboratory mice (BALB/C). Parasites were collected after 4 days. After filtering and washing, the concentration of protein in sonicated tachyzoites was calculated using the Lowry protein assay. The dilution of antigen, serum and alkaline phosphatase conjugate was assessed in designing an indigenous ELISA method; then ELISA was performed based on these dilutions, and its sensitivity was determined using 200 serum samples. In addition, the specificity of the assay was evaluated using 40 serum samples from patients with tuberculosis, leukemia or hydatid cyst.

Results: Indigenous ELISA was used to examine 100 serum samples containing anti-*T. gondii* IgG, with a sensitivity of 98% (commercial kits: 100%). Another 100 serum samples containing anti-*T. gondii* IgM were also tested, with a sensitivity of 99% (commercial kits: 100%). When 40 serum samples from patients with leukemia, hydatid cyst or tuberculosis were examined using anti-*T. gondii* IgG, the specificity was 100%, identical to commercial kits. However, the specificity of a similar test with anti-*T. gondii* IgM was just 28.6% for serum samples from leukemia patients, 21.4% for hydatid cyst and 16.7% for tuberculosis.

Conclusions: We found that purified locally isolated soluble crude antigens of the RH strain of *T. gondii* from the peritoneal cavity of mice may be one of the most promising antigens for detection of human toxoplasmosis in routine screening.

Keywords: *Toxoplasma gondii*, Designing, Indigenous ELISA, Tachyzoites RH Strain, Commercial Kits, Iran

1. Background

Toxoplasma gondii is one of the most important infectious diseases, having a worldwide distribution. Acquired toxoplasmosis is usually benign and asymptomatic, but it can be dangerous and have serious consequences in immunocompromised people and pregnant women. The disease is transmitted through consumption of contaminated water and food, as well as across the placenta in women whose first acute exposure to *T. gondii* occurs during pregnancy (1, 2). The prevalence of toxoplasmosis in humans varies depending on age, geographic region, temperature, humidity, eating habits and the presence of cats

in the home. About 30% to 60% of the world's human population is infected with *T. gondii* (3, 4).

Rapid and appropriate diagnosis of toxoplasmosis is of great importance, as timely diagnosis and appropriate treatment can significantly reduce complications of this disease (4). Inoculating a susceptible animal with a sample from the patient, performing a cell culture and observing the organism in tissue sections or a smear prepared from body fluids is a process with suitable sensitivity and specificity to diagnose toxoplasmosis; however, this technique is not usually used in medical diagnostic laboratories, due to the need for special facilities, the relatively long time

needed to determine the test result and the risk of human and environmental contamination. Detecting antibodies against *T. gondii* in an individual's serum is the common method to diagnose toxoplasmosis (5).

IgM antibodies are usually produced within the first week of the disease and usually decrease within a few months; however, in some cases, they persist for years. IgG-type antibodies are produced after one or two weeks, reach their maximum level within six months and then fall to a minimum within two years but remain present throughout the patient's life (4). Among the available methods to detect anti-*T. gondii* antibodies in serum, ELISA is the most suitable due to the simplicity of implementation, relatively high sensitivity, accessibility of materials and means in the form of commercially available kits and lack of need for expensive devices. Although methods such as immunoblotting and radioimmunoassay are also of suitable diagnostic value, they are not used in most medical diagnostic laboratories due to the complexity of implementation (4, 6).

The ELISA method does have some problems, including unacceptable false-positive and -negative results from kits; differing stability of immunoglobulins detectable by antigens used in these methods; and the incidence of false-positive results due to the presence of rheumatoid factors and natural antibodies, which complicate the interpretation of test results and the final test outcome (4, 7). Most of these problems are created by antigens used in the tests designed for this purpose. Past research has shown that the use of desirable antigens can lead to increased test sensitivity and decreased costs compared with commercial kits. In addition, diagnosing and distinguishing between the chronic and acute forms of this disease requires several serum tests performed at time intervals. This is important for the diagnosis of infection in pregnant women, as the parasite may be transmitted to the fetus during the period of diagnosis. Several studies have been conducted to identify compounds of *T. gondii* for use as antigens in serological tests designed to diagnose toxoplasmosis to resolve the above-mentioned problems (6, 7).

2. Objectives

In this study, an indigenous diagnostic ELISA kit was prepared and its sensitivities and specificities were compared with commercial kits using the above-mentioned strain antigens. The commercially available kits are all produced in other countries using non-Iranian RH antigens, which may affect the results. In this study, due to the high sensitivity and specificity of ELISA (98% - 99%) for the diagnosis of toxoplasmosis, this method is considered as the reference for the prepared indigenous kit.

3. Methods

3.1. Antigen Preparation

The local RH strain of *T. gondii* was prepared for ELISA testing according to the method described by Dahl and Johnson (8), with some modifications. Fifty male mice BALB/C with average weight of 25 - 30 gm, 5 - 6 weeks of age, were inoculated intraperitoneally with 0.02 mL of *T. gondii* RH strain parasite and 10^9 tachyzoites. After 4 days, 1 mL of sterile saline was injected intraperitoneally and then aspirated and examined under a light microscope. Next, 0.02 mL of the fluid was placed into the peritoneal cavity of other mice for maintenance. The fluid was centrifuged and washed with PBS containing Tris-buffered ammonium chloride and incubated in a water bath to destroy red blood cells. The suspension was centrifuged and washed and forced through a syringe (needle size 27) to release the tachyzoites from the peritoneal cells. These were filtered through polycarbonate membrane (pore size 3 mm), centrifuged and washed. After washing, the tachyzoites were counted and their viability was determined using trypan blue stain. The antigens were sonicated in an ice bath 5 times for 30 s and centrifuged at 12000 rpm for 45 min at 4°C. Protein concentration was determined using the method described by Lowry et al. (9).

3.2. Serum Samples

In this study, 200 serum samples from patients with *T. gondii* whose IgM and IgG antibodies had been detected using commercial kits were selected to assess the sensitivity of the prepared indigenous test. The specificity of the method was evaluated using 40 heterologous serum samples (10 serum samples each from groups of patients with tuberculosis, leukemia and hydatid cysts). The patients were confirmed to be healthy (having no anti-*T. gondii* IgG and IgM antibodies in their serum) using commercial ELISA kits. In addition, 200 negative-control serum samples were obtained from clinically healthy individuals.

3.3. Design of Indigenous ELISA Using Local Antigens from the RH Strain of *T. gondii*

The optimum dilutions were determined by checkerboard titration of antigen, serum and conjugate as described by Lind et al. (10), with some modifications. Microplates (Greiner, Germany) were coated with 100 μ L of sonicated tachyzoites of *T. gondii* RH strain with 0.3 mg/mL concentration, diluted 1:50 in carbonate buffer (pH = 9.6), and then incubated 180 min at 37°C.

The plates were washed three times with 300 μ L PBS containing 0.1% Tween 20 and blocked with 5% nonfat dry milk for 60 min at 37°C. After washing, 100 μ L of serum

sample, diluted 1:10 in PBS, was added and the microplate was incubated for 90 min at 37°C. After removing as above, 100 µL of alkaline phosphatase-labeled anti-goat conjugate (Sigma-Aldrich), diluted 1:3000 in PBS for IgG and 1:1000 for IgM, was added to the wells, and then the microplates were incubated at 37°C for 60 minutes. After removing, 100 µL of substrate solution (10 mg/mL 4-nitrophenylphosphate in 10 ml diethanolamine buffer, pH = 9.6) was added and the microplate was left for 30 min at room temperature. The reaction was stopped with 100 µL of 20% sulfuric acid, and the optical density at 450 nm was read in an ELISA reader (ELX800-Biotec). The cutoff value of optical densities (OD) was determined by the method of Hillyer et al. (11): the mean OD of negative control sera plus two standard deviations.

4. Results

The results obtained with commercial ELISA kits and ELISA using local antigens for *T. gondii* antibody detection were as follows. Serum samples from 100 healthy individuals were tested using indigenous ELISA with anti-*T. gondii* IgG, and the cutoff value with 95% confidence was detected to be 0.368. Similarly, serum samples from 100 healthy individuals were examined using ELISA with anti-*T. gondii* IgM, with a cutoff value of 0.369. Patient serum samples containing anti-*T. gondii* IgG tested positive with indigenous ELISA in 98 of 100 cases (98%); thus, the sensitivity of the test was estimated to be 98%. The sensitivity of commercial ELISA was 100% (Table 1).

The 100 patient serum samples containing anti-*T. gondii* IgM tested positive with indigenous ELISA in 99 cases (99%), establishing the sensitivity of the test as 99%, whereas the sensitivity of commercial ELISA was 100% (Table 2). There was no statistically significant difference between the tests (P value ≥ 0.05). To determine specificity, 40 serum samples were taken from patients with leukemia, hydatid cyst or tuberculosis. These samples, when examined with indigenous ELISA using anti-*T. gondii* IgG, gave a negative result in all 40 cases (100%). Thus, the specificity of the test was determined to be 100%, equivalent to commercial ELISA.

However, when the same samples were examined with indigenous ELISA using anti-*T. gondii* IgM, the results were 28.6% among leukemia patients, 21.4% for hydatid cyst patients and 16.7% for tuberculosis patients. Semiquantitative analysis using Pearson's correlation coefficient gave similar results: 0.69 R value and P ≤ 0.001 for the correlation between commercial and indigenous ELISA (Figure 1).




Figure 1. Graph of Pearson's Correlation Coefficient in 400 Samples Containing Anti-*T. gondii* IgG and IgM Using Indigenous ELISA and Commercial ELISA

5. Discussion

It is estimated that one third of the people in the world have been exposed to the parasite *T. gondii* (3). In Iran, toxoplasmosis continues to be a public health problem, and the seroprevalence of this infection is highly varied in different regions (2, 12-14). Khuzestan, southwest of Iran, is endemic for *T. gondii*. Previously, we have detected *T. gondii* from a variety of human and animal sources (1, 2, 15-17). Therefore, epidemiological study of the parasite is essential in this region.

One of the most commonly used screening methods for *T. gondii* infection is ELISA. ELISA is fast and easy to interpret, making it appropriate for routine screening of humans and having the potential for automatization (4, 6). One of the customary questions in this regard deals with the specificity and sensitivity of commercial ELISA kits. *T. gondii* is known to have different lineages, I, II and III, as well as genetic diversity in different parts of the world (17-21); could these characteristics affect the serological results? Accuracy of antigen preparation and standardization are important factors for researchers. Standardization of assays for *T. gondii*-specific antigens is also important for monitoring infection, as large differences in assay calibration could lead to misinterpretations of the clinical course when different assays are used. Furthermore, purchasing commercial kits can be a major problem for geographically remote or developing countries, where infectious diseases are typically the main public health problem. Therefore, preparation of indigenous diagnostic kits is very significant.

In the present study, we compared the sensitivity and specificity of standard ELISA assays using locally isolated antigens and using a commercial kit. The commercial ELISA kit gave more sensitive and more specific results

Table 1. Laboratory Results of Serum Samples Containing anti-*T. gondii* IgG from the RH Strain of *T. gondii* Using Indigenous ELISA

Number	OD	Number	OD	Number	OD	Number	OD
1	0.520	26	0.513	51	0.471	76	0.602
2	0.508	27	0.472	52	0.401	77	0.531
3	0.473	28	0.453	53	0.465	78	0.431
4	0.460	29	0.506	54	0.485	79	0.530
5	0.486	30	0.463	55	0.604	80	0.419
6	0.470	31	0.508	56	0.435	81	0.519
7	0.482	32	0.401	57	0.590	82	0.450
8	0.465	33	0.505	58	0.513	83	0.422
9	0.430	34	0.569	59	0.413	84	0.432
10	0.526	35	0.426	60	0.572	85	0.400
11	0.440	36	0.400	61	0.412	86	0.520
12	0.459	37	0.503	62	0.467	87	0.487
13	0.399	38	0.501	63	0.433	88	0.300
14	0.453	39	0.409	64	0.439	89	0.417
15	0.411	40	0.445	65	0.416	90	0.500
16	0.455	41	0.300	66	0.492	91	0.438
17	0.512	42	0.480	67	0.515	92	0.448
18	0.502	43	0.440	68	0.504	93	0.601
19	0.432	44	0.403	69	0.436	94	0.419
20	0.405	45	0.451	70	0.503	95	0.481
21	0.483	46	0.600	71	0.521	96	0.484
22	0.600	47	0.511	72	0.450	97	0.442
23	0.451	48	0.417	73	0.592	98	0.485
24	0.421	49	0.406	74	0.441	99	0.407
25	0.601	50	0.450	75	0.508	100	0.503

(both 100%) than the indigenous ELISA using anti-*T. gondii* IgG (98% and 99%). The specificity of indigenous ELISA using anti-*T. gondii* IgM was far less and probably proved a cross-reaction with other disease antigens. However, no statistically significant differences were found between the tests.

Our results can be compared with those in a 1995 study by Zhang et al. (88.9% sensitivity and 95.7% specificity)(22), a 1990 study by Malik et al. (62.5% sensitivity) (23), a 2007 study by Shaapan et al. (49% sensitivity with local antigens from the RH strain of *T. gondii*) (24), a 2011 study by Hasanain et al. (61.4% sensitivity) (25) and a 2013 study by Al-Olayan (50% sensitivity)(26). The higher level of sensitivity in our study might be linked to our antigen preparation methods and to our region. Most specificity in our study showed non-cross reaction. McCabe and Remington found in 1988 that the peritoneal fluid of mice infected with the

RH strain of *T. gondii* was able to characterize anti-*T. gondii* IgG in human serum (27). Yamamoto et al. reported in 1998 that the antigenic compounds in the peritoneal fluid of mice infected with tachyzoites of the RH strain of *T. gondii* accurately characterized anti-*T. gondii* IgG, IgM and IgA in human serum samples and could be utilized as an antigen in serological tests (28). Ghazy et al. recommended utilization of 65 kDa antigen of *T. gondii* in commercial kits for diagnosis of toxoplasmosis in human serum (29).

Our conclusion is that local antigens are more suitable than commercial antigens for this purpose, as they allow for easier preparation, less expense and greater sensitivity. We recommend utilization of soluble antigens obtained from locally isolated tachyzoites to diagnose toxoplasmosis in humans using ELISA, which showed statistically equivalent diagnostic potency and sensitivity in our study compared with a commercial ELISA kit.

Table 2. Laboratory Results of Serum Samples Containing anti-*T. gondii* IgM from the RH Strain of *T. gondii* Using Indigenous ELISA

Number	OD	Number	OD	Number	OD	Number	OD
1	0.637	26	0.651	51	0.423	76	0.432
2	0.853	27	0.546	52	0.525	77	0.660
3	0.451	28	0.620	53	0.425	78	0.485
4	0.448	29	0.434	54	0.435	79	0.522
5	0.538	30	0.412	55	0.511	80	0.410
6	0.528	31	0.514	56	0.426	81	0.506
7	0.729	32	0.499	57	0.601	82	0.462
8	0.551	33	0.453	58	0.501	83	0.460
9	0.645	34	0.508	59	0.408	84	0.520
10	0.456	35	0.601	60	0.520	85	0.415
11	0.438	36	0.446	61	0.451	86	0.541
12	0.616	37	0.450	62	0.440	87	0.416
13	0.482	38	0.503	63	0.635	88	0.650
14	0.433	39	0.430	64	0.850	89	0.536
15	0.661	40	0.615	65	0.431	90	0.619
16	0.486	41	0.532	66	0.422	91	0.433
17	0.483	42	0.647	67	0.518	92	0.411
18	0.523	43	0.410	68	0.721	93	0.513
19	0.412	44	0.540	69	0.551	94	0.452
20	0.507	45	0.413	70	0.643	95	0.507
21	0.464	46	0.498	71	0.409	96	0.300
22	0.462	47	0.402	72	0.455	97	0.600
23	0.416	48	0.522	73	0.437	98	0.445
24	0.542	49	0.511	74	0.615	99	0.449
25	0.417	50	0.711	75	0.481	100	0.500

Acknowledgments

The authors appreciate the support of the staff of the protozoology laboratory at the Jundishapur University of Medical Sciences.

Footnotes

Authors' Contribution: All authors had an equal role in the design, work, statistical analysis and writing of the paper.

Conflict of Interest: The authors declare that there is no conflict of interest regarding the publication of this paper.

Funding/Support: This study was conducted and financially supported by research deputy of Ahvaz Jundishapur University of Medical Sciences, Iran, as a Parasitology PhD

thesis of Mrs. Niloofar Mohammadpour, Medical Parasitology Department (Code NO:OG-94133).

References

1. Saki J, Shafieenia S, Foroutan-Rad M. Seroprevalence of toxoplasmosis in diabetic pregnant women in southwestern of Iran. *J Parasit Dis.* 2016 doi: [10.1007/s12639-015-0735-4](https://doi.org/10.1007/s12639-015-0735-4).
2. Foroutan-Rad M, Khademvatan S, Majidiani H, Aryamand S, Rahim F, Malehi AS. Seroprevalence of *Toxoplasma gondii* in the Iranian pregnant women: A systematic review and meta-analysis. *Acta Trop.* 2016;**158**:160-9. doi: [10.1016/j.actatropica.2016.03.003](https://doi.org/10.1016/j.actatropica.2016.03.003). [PubMed: [26952970](https://pubmed.ncbi.nlm.nih.gov/26952970/)].
3. Foroutan-Rad M, Majidiani H, Dalvand S, Daryani A, Kooti W, Saki J, et al. Toxoplasmosis in Blood Donors: A Systematic Review and Meta-Analysis. *Transfus Med Rev.* 2016;**30**(3):116-22. doi: [10.1016/j.tmr.2016.03.002](https://doi.org/10.1016/j.tmr.2016.03.002). [PubMed: [27145927](https://pubmed.ncbi.nlm.nih.gov/27145927/)].
4. Robert-Gangneux F, Darde ML. Epidemiology of and diagnostic strategies for toxoplasmosis. *Clin Microbiol Rev.* 2012;**25**(2):264-96. doi: [10.1128/CMR.05013-11](https://doi.org/10.1128/CMR.05013-11). [PubMed: [22491772](https://pubmed.ncbi.nlm.nih.gov/22491772/)].

5. Piergili Fioretti D. [Problems and limitations of conventional and innovative methods for the diagnosis of Toxoplasmosis in humans and animals]. *Parassitologia*. 2004;**46**(1-2):177-81. [PubMed: 15305712].
6. Montoya JG. Laboratory diagnosis of *Toxoplasma gondii* infection and toxoplasmosis. *J Infect Dis*. 2002;**185** Suppl 1:S73-82. doi: 10.1086/338827. [PubMed: 11865443].
7. Liesenfeld O, Press C, Montoya JG, Gill R, Isaac-Renton JL, Hedman K, et al. False-positive results in immunoglobulin M (IgM) toxoplasma antibody tests and importance of confirmatory testing: the Platelia Toxo IgM test. *J Clin Microbiol*. 1997;**35**(1):174-8. [PubMed: 8968902].
8. Dahl RJ, Johnson AM. Purification of *Toxoplasma gondii* from host cells. *J Clin Pathol*. 1983;**36**(5):602-4. [PubMed: 6841653].
9. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. Protein measurement with the Folin phenol reagent. *J Biol Chem*. 1951;**193**(1):265-75. [PubMed: 14907713].
10. Lind P, Haugegaard J, Wingstrand A, Henriksen SA. The time course of the specific antibody response by various ELISAs in pigs experimentally infected with *Toxoplasma gondii*. *Vet Parasitol*. 1997;**71**(1):1-15. [PubMed: 9231984].
11. Hillyer GV, Soler de Galanes M, Rodriguez-Perez J, Bjorland J, Silva de Lagrava M, Ramirez Guzman S, et al. Use of the Falcon assay screening test-enzyme-linked immunosorbent assay (FAST-ELISA) and the enzyme-linked immunoelectrotransfer blot (EITB) to determine the prevalence of human fascioliasis in the Bolivian Altiplano. *Am J Trop Med Hyg*. 1992;**46**(5):603-9. [PubMed: 1599055].
12. Daryani A, Sarvi S, Aarabi M, Mizani A, Ahmadpour E, Shokri A, et al. Seroprevalence of *Toxoplasma gondii* in the Iranian general population: a systematic review and meta-analysis. *Acta Trop*. 2014;**137**:185-94. doi: 10.1016/j.actatropica.2014.05.015. [PubMed: 24887263].
13. Sarkari B, Asgari Q, Bagherian N, Ashkani Esfahani S, Kalantari M, Mohammadpour I, et al. Molecular and Serological Evaluation of *Toxoplasma gondii* Infection in Reared Turkeys in Fars Province, Iran. *Jundishapur J Microbiol*. 2014;**7**(7):11598. doi: 10.5812/jjm.11598. [PubMed: 25368800].
14. Modrek MJ, Mousavi M, Saravani R. *Toxoplasma gondii* Seroprevalence Among Blood Donors in Zahedan, Southeastern Iran. *Int J Infect*. 2014;**1**(2):e21111. doi: 10.17795/iji-21111.
15. Saki J, Mohammadpour N, Moramezi F, Khademvatan S. Seroprevalence of *Toxoplasma gondii* in women who have aborted in comparison with the women with normal delivery in Ahvaz, southwest of Iran. *ScientificWorldJournal*. 2015;**2015**:764369. doi: 10.1155/2015/764369. [PubMed: 25699288].
16. Saki J, Khademvatan S. Detection of *Toxoplasma gondii* by PCR and mouse bioassay in rodents of Ahvaz district, southwestern Iran. *Biomed Res Int*. 2014;**2014**:383859. doi: 10.1155/2014/383859. [PubMed: 24605327].
17. Khademvatan S, Saki J, Yousefi E, Abdizadeh R. Detection and genotyping of *Toxoplasma gondii* strains isolated from birds in the southwest of Iran. *Br Poult Sci*. 2013;**54**(1):76-80. doi: 10.1080/00071668.2013.763899. [PubMed: 23444856].
18. Howe DK, Sibley LD. *Toxoplasma gondii* comprises three clonal lineages: correlation of parasite genotype with human disease. *J Infect Dis*. 1995;**172**(6):1561-6. [PubMed: 7594717].
19. Darde ML, Bouteille B, Pestre-Alexandre M. Isoenzyme analysis of 35 *Toxoplasma gondii* isolates and the biological and epidemiological implications. *J Parasitol*. 1992;**78**(5):786-94. [PubMed: 1403418].
20. de Sousa S, Ajzenberg D, Canada N, Freire L, da Costa JM, Darde ML, et al. Biologic and molecular characterization of *Toxoplasma gondii* isolates from pigs from Portugal. *Vet Parasitol*. 2006;**135**(2):133-6. doi: 10.1016/j.vetpar.2005.08.012. [PubMed: 16188390].
21. Fuentes I, Rubio JM, Ramirez C, Alvar J. Genotypic characterization of *Toxoplasma gondii* strains associated with human toxoplasmosis in Spain: direct analysis from clinical samples. *J Clin Microbiol*. 2001;**39**(4):1566-70. doi: 10.1128/JCM.39.4.1566-1570.2001. [PubMed: 11283088].
22. Zhang YW, Fraser A, Balfour AH, Wreghitt TG, Gray JJ, Smith JE. Serological reactivity against cyst and tachyzoite antigens of *Toxoplasma gondii* determined by FAST-ELISA. *J Clin Pathol*. 1995;**48**(10):908-11. [PubMed: 8537487].
23. Malik MA, Dreesen DW, de la Cruz A. Toxoplasmosis in sheep in north-eastern United States. *J Am Vet Med Assoc*. 1990;**196**(2):263-5. [PubMed: 2298651].
24. Shaapan RM, Hassanain A. Comparison of Horse Derived *Toxoplasma gondii* as Antigen with a Commercially Available ELISA Kit for the Detection of IgG Antibodies in human sera. *Glob Vet*. 2007;**1**(1):31-5.
25. Hassanain M, Elfadaly H, Shaapan R, Hassanain N, Barakat A. Biological assay of *Toxoplasma gondii* Egyptian mutton isolates. *Int J Zoological Res*. 2011;**7**(4):330-337. doi: 10.3923/ijzr.2011.330.337.
26. Al-Olayan E. Comparative serological diagnosis of toxoplasmosis in sheep using a crude antigen and commercial antigen. *Life Sci J*. 2013;**10**(4):3340-4.
27. McCabe R, Remington JS. Toxoplasmosis: the time has come. *N Engl J Med*. 1988;**318**(5):313-5. doi: 10.1056/NEJM198802043180509. [PubMed: 3336423].
28. Yamamoto YI, Mineo JR, Meneghisse CS, Guimaraes AC, Kawarabayashi M. Detection in human sera of IgG, IgM and IgA to excreted/secreted antigens from *Toxoplasma gondii* by use of dot-ELISA and immunoblot assay. *Ann Trop Med Parasitol*. 1998;**92**(1):23-30. [PubMed: 9614450].
29. Ghazy AA, Shaapan RM, Abdel-Rahman EH. Comparative serological diagnosis of toxoplasmosis in horses using locally isolated *Toxoplasma gondii*. *Vet Parasitol*. 2007;**145**(1-2):31-6. doi: 10.1016/j.vetpar.2006.11.010. [PubMed: 17174034].